阿里拉姆製藥 ALNY 深 滬
等待開盤 06-25 09:30:00 美东时间
294.06
+5.880
+2.04%
華盛通- 最 高303.46
- 今 開290.95
- 成交量 129.94万股
- 最 低 288.85
- 昨 收 288.18
- 總市值 392.61亿
- 52周最高 495.55
- 市盈率 靜 126.23
- 換手率 0.97%
- 52周最低 273.11
- 委 比 -66.67%
- 總股本 1.34亿
- 歷史最高 495.55
- 量 比 0.90
- 振 幅 5.07%
- 歷史最低 5.879
- 每 手 1
- 風險率 65.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ionis gains additional Tryngolza indication
The US FDA has approved an indicational indication for Ionis Pharmaceuticals' (IONS) Tryngolza (olezarsen) to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyc...
今天 04:18
美股异动丨阿里拉姆盘前涨2.37%，奥本海默重申买入及500美元目标价
格隆汇6月24日｜阿里拉姆制药(ALNY.US)盘前涨2.37%报295美元。消息上，奥本海默重申对阿里拉姆制药的看好立场，核心逻辑在于Amvuttra在AT...
06-24 17:01
Biotech breakout: iShares Biotechnology ETF hits all-time high
The biotechnology sector continued its advance on Tuesday, with the iShares Biotechnology ETF (IBB) reaching a record intraday high of $179.95 as investor interest in the industry remained strong. The...
06-24 02:52
Regeneron myasthenia gravis therapy undergoes U.S. and EU review
The U.S. and European regulators have accepted Regeneron’s (REGN) marketing applications for cemdisiran, an experimental therapy developed with Alnylam Pharmaceuticals (ALNY) for a rare autoimmune con...
06-24 02:34
Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 10 years by 3.79% on an annualized basis producing an average annual return of 17.65%. Currently, Alnylam Pharmaceuticals has a market capitalization of $37.36 billion. Buying $100 In ALNY: If an investor had bought $100...
06-22 23:45
Dyne Therapeutics Appoints Barry Greene to Board of Directors
Dyne Therapeutics announced the appointment of Barry Greene to its Board of Directors. With over three decades of experience in the biopharmaceutical industry, Greene brings a proven track record of building and scaling innovative companies across rare diseases, neuroscience, and oncology. His leadership includes roles at Sage Therapeutics and Alnylam Pharmaceuticals, where he contributed to the development and commercialization of novel therapie...
06-22 20:10
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
Regeneron's cemdisiran, an siRNA therapy targeting C5, has been accepted for review by the FDA and EMA for the treatment of anti-AChR antibody-positive generalized myasthenia gravis (gMG). The FDA is expected to make a decision by November 2026, while the European Commission's decision is anticipated in late 2027. Cemdisiran is administered subcutaneously every 12 weeks and has shown promise in the Phase 3 NIMBLE trial, results of which were publ...
06-22 11:00
美股大行评级 | 绩后暴跌，博通仍获11家大行上调目标价；CrowdStrike获21家大行集体上调目标价；Netskope、Veeva Systems惨遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Vivos Therapeutics"买入"评级，目标价从3美元升至3.1美元；富国银行：维持Veeva Systems"超配"评级，目标价从317美元升至320美元
06-05 11:33
Alnylam联手AI新锐Inceptive，最高20亿美元押注RNAi药物发现
受与人工智能公司达成战略合作的消息提振，Alnylam Pharmaceuticals股价周四上涨4%。该公司宣布与Inceptive Nucleics建立...
06-05 03:01
